Vincerx Pharma, Inc.
Other OTCTotal Valuation
Vincerx Pharma, Inc. carries a market capitalization of 66,475.00, placing it among publicly traded companies globally. Its enterprise value stands at -3.06M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 66,475.00 |
| Enterprise Value | -3.06M |
Share Statistics
Vincerx Pharma, Inc. currently has 5.23M shares outstanding.
| Shares Outstanding | 5.23M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.01 |
| P/TBV Ratio | 0.66 |
| P/FCF Ratio | -0.06 |
| P/OCF Ratio | -0.06 |
Financial Position
Vincerx Pharma, Inc. maintains a current ratio of 1.79, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.79 |
| Quick Ratio | 1.69 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -287.21 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Vincerx Pharma, Inc.'s stock has declined approximately -77.7193% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.03.
| Beta (5Y) | N/A |
| 52-Week Price Change | -77.7193% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.03 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -26.49M, while operating income came in at -27.32M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -27.32M |
| Pretax Income | -22.64M |
| Net Income | -22.64M |
| EBITDA | -26.49M |
| EBIT | -27.32M |
| Earnings Per Share (EPS) | -8.73 |
Balance Sheet
Total book value stands at -194.18M, with working capital of 2.07M providing operational flexibility.
| Cash & Cash Equivalents | 4.44M |
| Total Debt | N/A |
| Net Debt | -4.44M |
| Equity (Book Value) | -194.18M |
| Book Value Per Share | -74.87 |
| Working Capital | 2.07M |
Cash Flow
Vincerx Pharma, Inc. produced -22.84M in operating cash flow over the past twelve months.
| Operating Cash Flow | -22.84M |
| Capital Expenditures | N/A |
| Free Cash Flow | -22.84M |
| FCF Per Share | -8.81 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -1,590.89 |
| FCF Yield | -1,663.65 |
Stock Splits
Vincerx Pharma, Inc.'s most recent stock split took place on January 28, 2025 with a 20:1 split ratio.
| Last Split Date | 1/28/2025 |
| Split Ratio | 20:1 |
Scores
Vincerx Pharma, Inc. posts an Altman Z-Score of -76.41, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -76.41 |